1. Home
  2. LIQT vs BCDA Comparison

LIQT vs BCDA Comparison

Compare LIQT & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LiqTech International Inc.

LIQT

LiqTech International Inc.

HOLD

Current Price

$0.36

Market Cap

17.2M

Sector

Technology

ML Signal

HOLD

Logo BioCardia Inc.

BCDA

BioCardia Inc.

HOLD

Current Price

$0.98

Market Cap

15.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIQT
BCDA
Founded
2004
N/A
Country
Denmark
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.2M
15.7M
IPO Year
2011
2009

Fundamental Metrics

Financial Performance
Metric
LIQT
BCDA
Price
$0.36
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
138.5K
★ 149.0K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $479,000.00
Revenue This Year
$21.16
N/A
Revenue Next Year
$22.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.35
$0.75
52 Week High
$2.57
$1.80

Technical Indicators

Market Signals
Indicator
LIQT
BCDA
Relative Strength Index (RSI) 34.72 46.04
Support Level N/A $0.80
Resistance Level $0.74 $0.99
Average True Range (ATR) 0.06 0.07
MACD -0.01 -0.01
Stochastic Oscillator 18.11 45.85

Price Performance

Historical Comparison
LIQT
BCDA

About LIQT LiqTech International Inc.

LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is renowned in three business areas: ceramic membranes and membrane incorporated liquid filtration systems, ceramic diesel particulate filters (DPFs) to control soot exhaust particles and black carbon emission from diesel engines, and plastic components for usage across various industries. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, Hybrid Technology Membranes and others. The Company operates through three reportable segments: Systems and Aftermarket, Filters and Membranes, and Components.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: